[HTML][HTML] Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B …
Journal of clinical oncology, 2013•ncbi.nlm.nih.gov
Purpose The Programmed Death-1 (PD-1) immune checkpoint pathway may be usurped by
tumors, including diffuse large B-cell lymphoma (DLBCL), to evade immune surveillance.
The reconstituting immune landscape after autologous hematopoietic stem-cell
transplantation (AHSCT) may be particularly favorable for breaking immune tolerance
through PD-1 blockade.
tumors, including diffuse large B-cell lymphoma (DLBCL), to evade immune surveillance.
The reconstituting immune landscape after autologous hematopoietic stem-cell
transplantation (AHSCT) may be particularly favorable for breaking immune tolerance
through PD-1 blockade.
Abstract
Purpose
The Programmed Death-1 (PD-1) immune checkpoint pathway may be usurped by tumors, including diffuse large B-cell lymphoma (DLBCL), to evade immune surveillance. The reconstituting immune landscape after autologous hematopoietic stem-cell transplantation (AHSCT) may be particularly favorable for breaking immune tolerance through PD-1 blockade.
ncbi.nlm.nih.gov